Sanofi Agreement was Adagene’s largest revenue line in fiscal 2022, bringing in $8.99M of $9.29M (97%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 |
|---|---|
| Sanofi Agreement | $8.99M |
| Adct Material Transfer & Option Agreement | $300.00K |
| Total | $9.29M |
Adagene brought in $9.29M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Sanofi Agreement was the largest at $8.99M (96.8%), ahead of Adct Material Transfer & Option Agreement at $300.00K (3.2%).
Adagene (ADAG) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2022, Sanofi Agreement was its largest revenue line, bringing in $8.99M (96.8% of the total), followed by Adct Material Transfer & Option Agreement at $300.00K (3.2%).
Sanofi Agreement was Adagene's largest revenue line in fiscal 2022, bringing in $8.99M, or 96.8% of the $9.29M total across its two revenue lines.
Every figure comes from Adagene's annual financial filings, as reported. Each line keeps the name Adagene gives it, and years follow its fiscal calendar.
Adagene's revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2022, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.